The clinical syndrome of COVID-19 infection is complex and implies multiorgan involvement.

In this paper, recently published in the Journal of Neurology, the authors report neurological manifestations in 404 consecutive patients with COVID-19 seen in outpatient clinics and hospitalised between February 20, 2020 and May 4, 2020 at Evergreen Hospital, Kirkland, Washington, USA.

In this paper, recently published in Movement Disorders, the authors explored, through a structured questionnaire, the potential effects of COVID-19 pandemic and lockdown on cognition in Parkinson’s Disease (PD) patients. In particular, they studied 28 PD patients with cognitive disturbance (10 PD with subjective cognitive complaints [SCI]; 10 PD with mild cognitive impairment [MCI] and 8 PD with dementia [PDD]).

In this paper, recently published in the European Journal of Neurology, the authors identified and performed in depth clinical characterisation of a new type of delayed onset movement disorder in five patients who were admitted to the AP-HP intensive care unit (ICU) units for severe SARS-CoV-2 infection.

In this paper, recently published in Annals of Internal Medicine, the authors describe 3 patients without previous neurological or autoimmune disorders who were diagnosed with myasthenia gravis after the onset of coronavirus disease 2019 (COVID-19).

The EAN established MoUs with the ERN dedicated to Neuromuscular diseases and Rare Neurological Diseases.

The European Medicines Agency’s annual report 2019 is now available on the Agency’s website.

In this paper, recently published in Clinical Infectious Diseases, the authors report a laboratory confirmed SARS-CoV-2 re-infection in a patient which occurred 4.5 months after the first episode.

In this study, the authors examined the association of in-hospital anticoagulation (AC) in COVID-19 patients with in-hospital outcomes and described thromboembolic findings on autopsies.

In this longitudinal observational study. recently published in the Journal of the American Geriatrics Society, the authors investigate the occurrence of delirium in hospitalised patients with COVID‐19 and explore its association with adverse outcomes

This report, recently published in Annals of Internal Medicine, represents the second update of a previously published living systematic review (Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19.

he objective of this randomised, open-label trial, recently published in JAMA, was to determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status on day 11 after initiation of treatment in patients with moderate COVID-19 infection.

In this prospective study, the authors aimed to identify the existence of potential brain microstructural changes related to SARS-CoV-2 infection.

The aim of this study, recently published in the Journal of Neurology, Neurosurgery and Psychiatry was, by a systematic review of the reported cases of GBS in SARS-CoV-2 infection, to clarify the clinical and electrophysiological phenotype, to discuss, on the basis of the available data, whether the disease mechanism could be parainfective or postinfective and to speculate on the possible pathogenesis.

In this multicentre retrospective observational cohort study recently published in Lancet Rheumatology, the authors investigate the association between tocilizumab exposure and hospital-related mortality among patients requiring intensive care unit (ICU) support for COVID-19.